Pneumagen and PneumoWave announced product development funding and collaboration

PneumoWave and Pneumogen PR

Pneumagen and PneumoWave announced product development funding and collaboration

 

Equity Gap have invested in some of the leading life science and emerging digital health companies in Scotland. Today two of them announce significant milestones on their clinical trial and product journeys.

PneumoWave and King’s College London collaborate to lead the development of life-saving interventions to prevent drug-related deaths. 

Digital therapeutics company PneumoWave announced today the use of their monitoring platform in a clinical trial at King’s College London to collect breathing data from patients at risk of experiencing slow and shallow breathing – respiratory depression – as a side effect of opioid medication.  

Without treatment, respiratory depression can cause life-threatening complications, contributing directly to the annual toll of 150,000. The trial will lead to the development of life-saving interventions to prevent drug-related deaths – now the largest cause of accidental death in most developed countries. 

The trial is taking place in the National Institute for Health Research (NIHR)-Wellcome King’s Clinical Research Facility which is supported by the NIHR Maudsley Biomedical Research Centre and is part of a national program of clinical research as the company develops digital health and therapeutic solutions for a range of respiratory conditions. 

Dr Bruce Henderson, founder and CEO of PneumoWave, commented: “The technology behind PneumoWave was specifically developed to reduce deaths from respiratory conditions. The research facilities at King’s College London, and their highly skilled team, make it one of the few places in the world where the data we require can be safely captured.” 

Professor Sir John Strang, head of Addictions at IoPPN, King’s College London added: “Working together with my team, I am very excited about this new collaboration and its potential to apply science to make the world a safer place for one of our most vulnerable groups. With drug-related deaths at an all-time high in the UK and globally, we need to develop better ways to reduce this loss of life. It is essential that we drive new scientific studies and develop new technologies that have real potential to save lives.” 

Read the full story HERE.

 

PneumoWave Biosensor and Patient Gateway.

Picture 1: PneumoWave Biosensor and Patient Gateway.

Pneumagen raises £3.8 million for the Prophylaxis and treatment of Viral Respiratory Tract Infections, including SARS-CoV-2 with a self-administered intranasal product.    

Pneumagen, a clinical-stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announced it has raised a further £3.8m to advance clinical development and manufacturing of its lead product Neumifil.   

Neumifil is being developed to offer pan-antiviral protection against respiratory viruses such as influenza, respiratory syncytial virus (RSV) and coronaviruses including SARS-CoV-2 with a self-administered intranasal product.  Currently, Neumifil is being assessed in a Phase I study with top-line results anticipated in the first half of 2022.   

Neumifil has shown potent anti-viral activity against a broad range of infections caused by influenza viruses, RSV and SARS-CoV-2 in pre-clinical studies, and its differentiated mechanism of action means it is less susceptible to direct viral resistance. 

Douglas Thomson, CEO of Pneumagen, commented: “Neumifil has the potential to significantly improve the lives of patients suffering from viral respiratory tract infections. As a pan-antiviral, easy to use, self-administered novel treatment option, Neumifil has the potential to have a significant impact on decreasing the risk of hospitalisation and death, through the prevention and treatment of multiple respiratory viral infections, for patients who suffer from viral exacerbations of underlying chronic lung disease.” 

Thairm Bio’s Mark Bamforth said: “We are pleased to provide this financing to Pneumagen, which reflects the great confidence we have in the Company’s business strategy and execution, the highly committed management team and the significant potential of Neumifil to become a key treatment option for patients with a broad range of viral RTIs.” 

Read the full story HERE 

Nasal inhalation device prototype for delivery of Neumifil

Picture 2: Nasal inhalation device prototype for delivery of Neumifil.